Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Long-Term Capital Lease Obligation : ¥1.9 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Ausun Pharmaceutical Co Long-Term Capital Lease Obligation?

Zhejiang Ausun Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥1.9 Mil.

Zhejiang Ausun Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation increased from Mar. 2024 (¥2.1 Mil) to Jun. 2024 (¥2.1 Mil) but then declined from Jun. 2024 (¥2.1 Mil) to Sep. 2024 (¥1.9 Mil).

Zhejiang Ausun Pharmaceutical Co's annual Long-Term Capital Lease Obligation stayed the same from Dec. 2021 (¥0.0 Mil) to Dec. 2022 (¥0.0 Mil) but then increased from Dec. 2022 (¥0.0 Mil) to Dec. 2023 (¥2.0 Mil).

Zhejiang Ausun Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Zhejiang Ausun Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Ausun Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Zhejiang Ausun Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.04

Zhejiang Ausun Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	2.04	2.07	2.10	1.88

Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Zhejiang Ausun Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zhejiang Ausun Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Ausun Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang Ausun Pharmaceutical Co Ltd (SHSE:603229) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.5, Donghai 4th Avenue, chemical raw materials base Linhai Park East, Zhejiang Province, Taizhou, CHN, 317016

Website

http://www.ausunpharm.com

Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.

Executives

Zheng Zhi Guo	Directors, senior managers
Zhang Hua Dong	Directors, senior managers
Liu Bing	Director

Zhejiang Ausun Pharmaceutical Co Headlines

No Headlines